Format

Send to

Choose Destination
Eur J Breast Health. 2017 Oct 1;13(4):162-167. doi: 10.5152/ejbh.2017.3635. eCollection 2017 Oct.

Reliable Biomarkers to Identify New and Recurrent Cancer.

Author information

1
Department of Surgery, Hartford Hospital and University of Connecticut School of Medicine, Hartford, USA.

Abstract

Breast cancer is the most frequent cancer detected throughout both the developing and the developed world. Its incidence is on the rise in the developing world. Great strides have been made in developing biomarkers to guide therapy for women diagnosed with breast cancer. Far fewer advances have occurred with biomarker development for the early diagnosis of breast cancer. Standard screening for new and recurrent breast cancer involves clinical breast exam and breast imaging. There are no Food and Drug Administration (FDA) approved noninvasive body fluid tests for the early detection of new or recurrent breast cancer. Promising biomarker approaches include multianalyte testing of tissue for individuals diagnosed with breast cancer and body fluid analysis for both at risk women and to monitor individuals after treatment.

KEYWORDS:

Breast cancer; biomarkers; carbohydrates; lipids; proteins

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the author.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center